Gholamreza Khamisipour

Dr. Gholamreza Khamisipour


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in BioMed Research International
Verified
Journal Article
Open access
PDF file
DIDarioush Iranpour
Darioush Iranpour
MHMojtaba Hassanpour
Mojtaba Hassanpour
HAHossein Ansari
Hossein Ansari
STSaeed Tajbakhsh
Saeed Tajbakhsh
GKGholamreza Khamisipour
Gholamreza Khamisipour
ANAkram Najafi
Akram Najafi
Objectives.In 2013, Clermont classifiedE. colistrains into eight phylogenetic groups using a new quadruplex PCR method. The aims of this study were to identify the phylogenetic groups ofE. colibased on this method and to assess their antibiotic resistance patterns in Bushehr, Iran.Methods. In this cross-sectional study, 140E. coliisolates were subjected to phylogenetic typing by a quadruplex PCR method. Antimicrobial susceptibility testing was performed by disk diffusion method.Results. Phylogenetic group B2 was most predominant (39.3%), followed by unknown (27.1%), E (9.3%), C and clade I (each 6.4%), B1 (5%), F and D (each 2.9%), and A (0.7%). The most common antibiotic resistance was related to amoxicillin (82.1%) and the least to meropenem (0.7%). 82.14% of isolates were multiple drug resistant (MDR). Antibiotic resistance was mainly detected in group B2 (50%).Conclusions.Our findings showed the high prevalence of MDRE. coliisolates with dominance of group B2. About 25% ofE. coliisolates belong to the newly described phylogroups C, E, F, and clade I. Such studies need to be done also in other regions to provide greater understanding of the antibiotic resistance pattern and the prevalences of different phylogenetic groups.

7 May 2016 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
GKGholamreza Khamisipour
Gholamreza Khamisipour
FJFarhad Jadidi-Niaragh
Farhad Jadidi-Niaragh
AJAbdolreza Sotoodeh Jahromi
Abdolreza Sotoodeh Jahromi
KZKeivan Zandi
Keivan Zandi
Mohammad Hojjat-FarsangiMohammad Hojjat-Farsangi
Mohammad Hojjat-Farsangi

1 September 2018 in Gene
Verified
Journal Article
Closed access
MAMohammad Foad Abazari
Mohammad Foad Abazari
FSFatemeh Soleimanifar
Fatemeh Soleimanifar
MAMaryam Nouri Aleagha
Maryam Nouri Aleagha
STSepehr Torabinejad
Sepehr Torabinejad
NNNavid Nasiri
Navid Nasiri
MKMousa Kehtari
Mousa Kehtari


21 January 2016 in Oncology Research
Verified
Journal Article
Open access
ECEncieh Choghaei
Encieh Choghaei
GKGholamreza Khamisipour
Gholamreza Khamisipour
MFMojtaba Falahati
Mojtaba Falahati
BNBehrooz Naeimi
Behrooz Naeimi
MMMajid Mossahebi-Mohammadi
Majid Mossahebi-Mohammadi
ZHZahra Sadat Hashemi
Zahra Sadat Hashemi
Breast cancer is the most commonly occurring cancer among women. MicroRNAs as noncoding small RNA molecules play pivotal roles in cancer-related biological processes. Increased levels of microRNA-29a in the serum of breast cancer patients have been reported. Since heat shock proteins (HSPs) play important roles in cell events, the quantitative fluctuations in their cellular levels could be deemed as key indicators of how the exerted treatment alters cell behavior. In this regard, using an antisense small RNA, we attempted to investigate the effects of miR-29a knockdown on the expression of HSPs genes in the MCF-7 breast cancer cell line. MCF-7 cells were cultured in high-glucose Dulbecco’s modified Eagle’s medium with 10% FBS. Studied cells were subdivided into five groups: treated with scramble, anti-miR-29a, anti-miR-29a + Taxol, Taxol, and control. Taxol was added 24 h post-anti-miR transfection and RNA extraction, and cDNA synthesis was done 48 h later. The changes in expression of HSP27, HSP40, HSP60, HSP70, and HSP90 were evaluated by real-time PCR. Our results revealed that inhibitors of microRNA-29a promote apoptosis through upregulation of HSP60 level and downregulation of HSP27, HSP40, HSP70, and HSP90 levels and could be contemplated as a compelling alternative for Taxol employment with similar effects and/or to sensitize cancer cells to chemotherapy with fewer side effects.

1 September 2023
Verified
Journal Article
Closed access
ZZZivar Zangeneh
Zivar Zangeneh
GKGholamreza Khamisipour
Gholamreza Khamisipour